MERCK KGAA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 151.8 EUR | +1.10% |
|
+3.94% | +5.31% |
| Apr. 26 | Former SAP Executive Board member Kleinemeier to permanently head Merck's Supervisory Board | DP |
| Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- With an enterprise value anticipated at 3.39 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +5.31% | 69.91B | A | ||
| +10.97% | 9.03B | A- | ||
| -16.83% | 4.75B | A- | ||
| +43.48% | 4.31B | - | ||
| +3.20% | 3.88B | B- | ||
| +18.82% | 2.37B | B | ||
| -21.36% | 2.26B | C- | ||
| -29.67% | 2.2B | - | ||
| +8.38% | 1.98B | - | - | |
| -0.50% | 1.64B | - | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA
